Cyclacel Pharmaceuticals (NASDAQ:BGMS) Posts Quarterly Earnings Results

Cyclacel Pharmaceuticals (NASDAQ:BGMS) released its quarterly earnings results on Friday. The company reported ($0.08) earnings per share for the quarter, FiscalAI reports. The firm had revenue of $0.34 million for the quarter.

Cyclacel Pharmaceuticals Trading Down 1.1%

Shares of BGMS traded down $0.01 during trading hours on Friday, reaching $0.92. 4,374 shares of the stock traded hands, compared to its average volume of 35,864. Cyclacel Pharmaceuticals has a 52 week low of $0.57 and a 52 week high of $9.40. The stock has a fifty day simple moving average of $0.88 and a 200 day simple moving average of $0.97. The company has a market cap of $5.05 million, a price-to-earnings ratio of -0.20 and a beta of -0.38.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised Cyclacel Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday, July 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies that target the cell cycle and related regulatory pathways for the treatment of cancer and other proliferative diseases. The company’s research and development efforts center on kinase and cell-cycle inhibitors designed to disrupt tumor growth and induce cancer cell death. Cyclacel advances programs through preclinical development and clinical trials with the aim of delivering new therapeutic options for patients with solid tumors and hematologic malignancies.

Key activities at Cyclacel include in-house drug discovery, translational research, and the clinical development of lead candidate molecules.